SOBER

About Synlife

Synlife is an early-stage biotechnology company developing a novel therapeutic platform based on engineered Synthetic Cells. Its lead program, SOBER, targets the rapid removal of ethanol from the blood for alcohol poisoning, while a second program aims to locally activate chemotherapeutics within solid tumors. The company is privately held, pre-revenue, and backed by venture capital and government grants, positioning itself at the intersection of advanced drug delivery and synthetic biology.

Therapeutic Areas